Education
About Us
Working with TipRanks
Follow Us
OrthoPediatrics Corp (KIDS)
NASDAQ:KIDS
KIDS Stock Chart & Stats
$17.31
-$0.10(-0.41%)
At close: 4:00 PM EST
$17.31
-$0.10(-0.41%)
Day’s Range― - ―
52-Week Range$15.28 - $26.40
Previous CloseN/A
Volume20.12K
Average Volume (3M)196.93K
Market Cap
$437.58M
Enterprise Value$466.38M
Total Cash (Recent Filing)$60.85M
Total Debt (Recent Filing)$48.36M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 06, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding25,278,788
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-59.19
Forecast
1Y Price Target
$24.88Price Target Upside43.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$263.18M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow ImprovementCompany generated positive free cash flow and materially reduced cash usage, improving funding flexibility and reducing reliance on external financing.
Regulatory Approvals And International ExpansionMultiple international regulatory clearances and beta product launches open new markets and create a clear path for meaningful overseas revenue contributions.
Revenue And Product MomentumReported revenue outperformed expectations while ongoing momentum across core product lines and recent product launches supports continued commercial growth.
Bears Say
Guidance And Operational ConstraintsCompany provided guidance that sets adjusted profitability below market consensus and plans lower deployment of surgical sets, which could pressure near-term earnings visibility.
Profitability Execution RiskAdjusted EBITDA missed analyst expectations, highlighting execution risk around achieving targeted profitability and margin improvement.
Quarterly Volatility And Analyst RevisionsQuarter-to-quarter volatility combined with negative analyst revisions may weaken investor sentiment and limit valuation multiple expansion.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $15.28 and its highest was $26.40 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $437.58M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is May 06, 2026 which is in 53 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Feb 26, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.028.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.47.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 25,278,788 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 7.757%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.88 (43.73% Upside)
$24.88 (43.73% Upside)
Blogger Sentiment
Bullish
KIDS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 60.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
-12.67%
Trailing 12-Months
Asset Growth
0.86%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
KIDS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial trajectory: strong top-line growth (Q4 +17%, FY +15%), meaningful margin expansion (Q4 gross margin 73%), material adjusted EBITDA improvement, and the first quarter of positive free cash flow contributing to a major year-over-year cash usage improvement (down $26M or 63%). The company also highlighted a deep product pipeline, multiple regulatory and commercial milestones (including EU MDR approvals and FDA clears), and reiterated confident 2026 targets (revenue $262–$266M, ~$25M adjusted EBITDA, free cash flow breakeven). Offsets include continued GAAP and non-GAAP losses, elevated G&A spending, timing-related R&D variability, early-stage digital/adjacency initiatives with limited near-term revenue, and seasonal cash-flow volatility. Overall, the favorable financial inflection, product momentum, and guidance credibility outweigh the remaining execution and timing risks.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$24.88
▲(43.73% Upside)
Technical Analysis
Orthofix Medical
―
Tandem Diabetes Care
―
Varex Imaging
―
Bioventus
―
Treace Medical Concepts
―
Ownership Overview
32.72% Insiders
14.71% Mutual Funds
21.16% Other Institutional Investors
23.61% Public Companies and
Individual Investors